Endoxifen-d5

Endoxifen-d5 is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

Product Specifications

CAS Number

[1185244-45-4]

UNSPSC

12352005

Hazard Statement

H302, H312, H332, H361, H413

Target

Cytochrome P450; Drug Metabolite; Estrogen Receptor/ERR; Parasite

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer

Purity

97.52

Solubility

10 mM in DMSO

Smiles

[2H]C([2H])([2H])C([2H])([2H])/C(C1=CC=CC=C1)=C(C2=CC=C(C=C2)O)/C3=CC=C(C=C3)OCCNC

Molecular Formula

C25H22D5NO2

Molecular Weight

378.52

Precautions

H302, H312, H332, H361, H413

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Goetz MP, et al. Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor. Oncology (Williston Park) . 2009 Dec;23 (14) :1233-4, 1236.|[3]Wu X, et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 2009 Mar 1;69 (5) :1722-7.